# Mark Egly Foundation - Mission, Vision & Values

**Document Version**: 1.0  
**Last Updated**: November 7, 2025  
**Owner**: Board of Directors  
**Purpose**: Define the foundation's north star, guiding principles, and core identity

---

## üéØ Mission Statement

> **The Mark Egly Foundation exists to eliminate diagnostic delays and improve outcomes for individuals affected by Alpha-1 Antitrypsin Deficiency through education, research, advocacy, and compassionate support.**

We achieve this by:
- **Educating** medical professionals to recognize and diagnose AATD early
- **Supporting** patients and families through testing, treatment, and community
- **Advancing** research into better detection, treatment, and prevention
- **Advocating** for policy changes that protect and empower AATD patients
- **Innovating** new technologies and approaches to AATD care

---

## üåü Vision Statement

> **A world where no one suffers from undiagnosed Alpha-1 Antitrypsin Deficiency.**

**By 2035**, we envision:
- **Universal newborn screening** for AATD in all 50 states
- **Diagnostic delay reduced** from 7-8 years to less than 1 year
- **Every physician** trained to recognize AATD symptoms
- **Comprehensive support systems** for every AATD patient
- **Breakthrough treatments** resulting from accelerated research
- **AATD recognized** as a protected condition with full insurance coverage

We will transform AATD from an overlooked orphan disease into a well-understood, treatable condition with early detection protocols and robust patient support.

---

## üíô Core Values

### 1. **Patient First** ü´Å

**Definition**: Every decision prioritizes the health, dignity, and well-being of AATD patients and their families.

**In Practice**:
- Listen deeply to patient experiences and needs
- Design programs based on patient feedback
- Measure success by patient outcomes, not just metrics
- Ensure accessibility of all resources (no patient left behind)
- Treat patients as partners, not beneficiaries

**Why It Matters**: Mark's journey of self-diagnosis after years of struggle reminds us that patients are experts in their own experience. We exist to serve them.

---

### 2. **Urgency** ‚è∞

**Definition**: Every day of diagnostic delay is a day of preventable suffering. We act with purpose and speed.

**In Practice**:
- Prioritize high-impact initiatives that save time
- Move quickly from strategy to implementation
- Embrace calculated risks to accelerate progress
- Streamline processes to reduce bureaucracy
- Celebrate quick wins while pursuing long-term goals

**Why It Matters**: The average 7-8 year diagnostic delay costs lives, lung function, and quality of life. We cannot afford to move slowly.

---

### 3. **Evidence-Based** üî¨

**Definition**: Science, data, and research guide our decisions. We commit to intellectual rigor and continuous learning.

**In Practice**:
- Base programs on peer-reviewed research
- Measure impact rigorously and transparently
- Partner with credible academic and medical institutions
- Pivot when evidence suggests a better approach
- Share data openly to advance collective knowledge

**Why It Matters**: AATD is a medical condition requiring medical solutions. Credibility comes from scientific integrity.

---

### 4. **Collaboration Over Competition** ü§ù

**Definition**: We partner generously with other organizations, researchers, and stakeholders to maximize collective impact.

**In Practice**:
- Share resources, knowledge, and best practices freely
- Celebrate other organizations' successes
- Build coalitions rather than work in silos
- Seek partnerships that amplify our reach
- Credit collaborators and contributors prominently

**Why It Matters**: AATD affects too few people for organizations to compete. Together, we are stronger.

---

### 5. **Innovation** üí°

**Definition**: We challenge the status quo and pioneer new approaches to AATD detection, treatment, and support.

**In Practice**:
- Invest in breakthrough technologies (AAT glucometer, rapid testing)
- Commercialize Mark's patent to fund research and expand access
- Experiment with novel programs (data donation tax deduction)
- Learn from failures and iterate quickly
- Think beyond traditional nonprofit models

**Why It Matters**: Incremental improvement won't solve the diagnostic delay crisis. Bold innovation is required.

---

### 6. **Transparency** üîç

**Definition**: We operate with openness, honesty, and accountability to donors, patients, and partners.

**In Practice**:
- Publish financials and impact reports publicly
- Admit mistakes and share lessons learned
- Make decision-making processes clear
- Welcome feedback and constructive criticism
- Protect patient privacy while sharing aggregate insights

**Why It Matters**: Trust is earned through transparency. Donors and patients deserve to see exactly how we operate.

---

### 7. **Hope** üåÖ

**Definition**: We inspire optimism and possibility for AATD patients, even in the face of a chronic condition.

**In Practice**:
- Tell stories of thriving, not just surviving
- Celebrate milestones, big and small
- Connect newly diagnosed patients with community
- Frame AATD as manageable with proper care
- Emphasize what's possible, not just what's difficult

**Why It Matters**: A diagnosis of AATD can be terrifying. We provide hope that a full, meaningful life is possible.

---

## üé≠ Our Story: Why We Exist

### Mark Egly's Journey

Mark Egly is a PGA Member who experienced firsthand the devastating consequences of delayed AATD diagnosis. Like thousands of others, Mark:
- Suffered from symptoms for years
- Saw multiple doctors who missed the diagnosis
- Eventually **self-diagnosed** after extensive research
- Lost precious time and lung function due to the delay

### The Diagnostic Delay Crisis

**The current reality**:
- Average time to diagnosis: **7-8 years**
- Average number of physicians consulted: **4+**
- Common misdiagnoses: Asthma, COPD, allergies
- Outcome: Preventable lung damage, delayed treatment

**Why delays happen**:
- AATD is an "orphan disease" (rare, often overlooked)
- Physicians aren't trained to look for it
- Symptoms mimic more common conditions
- No standard screening protocols exist
- Genetic testing not routinely offered

### The Hidden Population: MZ Carriers

Emerging science reveals that even **heterozygous carriers** (one mutated gene) like Mark's children can experience health impacts:
- Increased lung disease risk with environmental exposures
- Potential liver involvement
- Previously dismissed as "just carriers"
- Millions of Americans may be affected

This discovery expands the urgent need for:
- **Carrier awareness and education**
- **Monitoring protocols for MZ individuals**
- **Research into single-gene impacts**
- **Family cascade testing**

### Mark's Patent: Turning Innovation into Impact

Mark secured **US Patent 20220160847** for repurposing Alpha-1 Antitrypsin protein for:
- Treatment of other diseases
- Protection for firefighters (smoke inhalation)
- Asthma management
- Military applications (combat exposures)
- Novel delivery methods

**Foundation Impact**:
- Licensing revenue funds patient assistance
- Advances treatment accessibility
- Demonstrates innovation leadership
- Creates sustainable funding model

### Why This Foundation Matters

**No one should have to self-diagnose a genetic condition.**

The Mark Egly Foundation exists because:
1. **Patients deserve faster answers** - 7-8 years is unacceptable
2. **Physicians need better education** - AATD must be on their radar
3. **Research needs acceleration** - Innovations like the AAT glucometer can save lives
4. **Families need support** - Navigating AATD shouldn't be a solo journey
5. **Policy must change** - Newborn screening should be universal

---

## üåç Who We Serve

### Primary Beneficiaries

**1. Undiagnosed AATD Patients** (Largest Need)
- Currently misdiagnosed with asthma, COPD, or "unknown lung disease"
- Suffering preventable decline
- Unaware genetic testing is available
- **Our Impact**: Education campaigns help them get diagnosed faster

**2. Newly Diagnosed AATD Patients**
- Overwhelmed by diagnosis
- Need guidance on treatment options
- Seeking community and support
- **Our Impact**: Patient navigation, support groups, resources

**3. Diagnosed AATD Patients Managing Their Condition**
- Living with AATD long-term
- May need financial assistance for treatment
- Benefit from community and research updates
- **Our Impact**: Assistance programs, community, hope for better treatments

**4. MZ Carriers** (One Mutated Gene)
- Mark's children and millions of others
- New science shows they may be at risk
- Need monitoring and awareness
- **Our Impact**: Education on carrier risks, monitoring protocols

**5. At-Risk Family Members**
- Children, siblings, parents of diagnosed patients
- Should be tested due to genetic inheritance
- Often unaware of their risk
- **Our Impact**: Cascade testing advocacy and education

### Secondary Beneficiaries

**6. Medical Professionals**
- Need AATD education to diagnose earlier
- Want to avoid malpractice risk from missed diagnoses
- Benefit from diagnostic protocols and CME courses
- **Our Impact**: Physician education, certification programs

**7. Researchers & Innovators**
- Need patient data and funding for studies
- Developing new tests, treatments, devices
- Accelerating scientific understanding
- **Our Impact**: Research grants, data sharing, partnerships

**8. High-Risk Occupational Groups**
- Firefighters (smoke exposure accelerates AATD)
- Military personnel (burn pits, combat exposures)
- Industrial workers (chemical exposures)
- **Our Impact**: Targeted screening, occupational health advocacy

---

## üéØ Strategic Focus Areas

### 1. Education (Awareness & Knowledge)

**Medical Education**:
- CME courses for physicians on AATD recognition
- Medical school curriculum integration
- Diagnostic protocol development
- "AATD Aware" certification seal for institutions

**Patient Education**:
- "What is AATD?" comprehensive guides
- Living with AATD handbooks
- Testing and diagnosis roadmaps
- Treatment options education
- Family cascade testing information

**Public Awareness**:
- "Not all asthma is asthma" campaigns
- AATD risk factor education
- Community storytelling and visibility
- Media partnerships

**Target Outcome**: Every physician knows to test for AATD; every patient knows resources exist.

---

### 2. Research (Innovation & Discovery)

**Applied Research**:
- **AAT "Glucometer"** - Portable device to measure circulating AAT
- **Rapid DNA testing** - Faster, easier genetic testing
- **ZZ protein identification** - Simpler diagnostic tools
- **Novel administration methods** - Better drug delivery

**Foundational Research**:
- MZ carrier health impact studies
- Mass AAT protein production techniques
- Gene therapy partnerships
- Repurposing research (Mark's patent applications)

**Data Infrastructure**:
- Anonymous genetic data donation program
- Tax-deductible DNA sequence contributions
- Centralized research database
- Data sharing with qualified researchers

**Target Outcome**: Breakthrough innovations that reduce diagnostic time and improve treatment.

---

### 3. Advocacy (Policy & Systems Change)

**Legislative Priorities**:
- **Newborn screening** - AATD included in all state panels
- **Protected status** - AATD recognized as protected condition
- **Insurance coverage** - Testing and treatment fully covered
- **Occupational health** - Mandatory screening for high-risk jobs

**Healthcare System Change**:
- Standard AATD testing protocols in primary care
- Differential diagnosis guidelines (asthma vs. AATD)
- Genetic counseling availability
- Cascade testing requirements

**Occupational Health Policy**:
- Firefighter pre-employment AATD screening
- Military screening for AATD before deployment
- Worker's compensation for occupational AATD progression

**Target Outcome**: Systemic barriers to early diagnosis removed through policy change.

---

### 4. Support (Patient Assistance & Community)

**Financial Assistance**:
- Testing grants (genetic testing, pulmonary function)
- Treatment assistance (AAT augmentation therapy)
- Travel grants (specialist consultations)
- Emergency assistance (urgent needs)

**Patient Navigation**:
- One-on-one guidance through diagnosis and treatment
- Connection to specialists
- Insurance advocacy support
- Care coordination

**Community Building**:
- Support groups (virtual and in-person)
- Alpha1Life.com patient community platform
- Peer mentorship programs
- Family support networks
- Annual patient conferences

**Emotional Support**:
- Mental health resources
- Newly diagnosed support
- Caregiver support
- Bereavement support

**Target Outcome**: No AATD patient feels alone or unsupported.

---

## üìä Theory of Change (Simplified)

```
IF we educate physicians about AATD...
  THEN more patients will be diagnosed earlier
  
IF patients are diagnosed earlier...
  THEN they can start treatment sooner
  
IF treatment starts sooner...
  THEN lung function is preserved and outcomes improve
  
IF we support patients through their journey...
  THEN they thrive rather than just survive
  
IF we advocate for policy changes...
  THEN systemic barriers to early diagnosis are removed
  
IF we fund innovative research...
  THEN we accelerate breakthroughs in detection and treatment

ULTIMATE OUTCOME:
AATD transforms from an overlooked orphan disease 
with devastating diagnostic delays into a well-understood, 
manageable condition with early detection, effective treatment, 
and comprehensive support.
```

---

## üèÜ Success Looks Like... (2035 Vision)

### For Patients
- ‚úÖ Diagnosed within **1 year** of symptom onset (not 7-8 years)
- ‚úÖ Every diagnosed patient connected to **support community**
- ‚úÖ Financial barriers to testing and treatment **eliminated**
- ‚úÖ Quality of life **preserved** through early intervention
- ‚úÖ Families **educated and tested** proactively

### For Medical System
- ‚úÖ **All 50 states** include AATD in newborn screening
- ‚úÖ Primary care physicians **routinely test** for AATD
- ‚úÖ Medical schools **teach AATD** in standard curriculum
- ‚úÖ Differential diagnosis protocols **widely adopted**
- ‚úÖ Genetic testing **affordable and accessible**

### For Research & Innovation
- ‚úÖ **AAT glucometer** commercially available
- ‚úÖ Mark's patent applications **improving lives**
- ‚úÖ **Gene therapy** trials showing promise
- ‚úÖ MZ carrier health impacts **fully understood**
- ‚úÖ New treatments **in development pipeline**

### For Policy & Systems
- ‚úÖ AATD recognized as **protected condition**
- ‚úÖ **Insurance mandates** cover testing and treatment
- ‚úÖ Firefighters and military **routinely screened**
- ‚úÖ Occupational health standards **include AATD**
- ‚úÖ Malpractice precedents **established** for missed diagnoses

### For the Foundation
- ‚úÖ **10,000+ patients** assisted annually
- ‚úÖ **$10M+** in research grants distributed
- ‚úÖ **100,000+** physicians trained
- ‚úÖ **Financially sustainable** through diverse revenue
- ‚úÖ **National model** for orphan disease advocacy

---

## ü§ù Our Commitments

### To Patients
**We promise to**:
- Listen to your experiences and prioritize your needs
- Provide accurate, accessible information
- Connect you with resources and community
- Advocate fiercely for your rights and access to care
- Treat you with dignity, respect, and compassion
- Never give up on finding better solutions

---

### To Donors
**We promise to**:
- Use your contributions wisely and transparently
- Report impact honestly and regularly
- Maintain the highest ethical standards
- Innovate to maximize every dollar's impact
- Thank you meaningfully and often
- Invite you into our community and mission

---

### To Medical Professionals
**We promise to**:
- Provide evidence-based, credible education
- Respect your time with efficient, practical tools
- Support you in serving AATD patients well
- Partner, not lecture or blame
- Stay current with evolving research
- Recognize your critical role in early diagnosis

---

### To Researchers
**We promise to**:
- Fund impactful, well-designed studies
- Share data and resources generously
- Streamline administrative burden
- Celebrate and publicize your contributions
- Foster collaboration across institutions
- Accelerate the path from discovery to patients

---

### To Mark's Legacy
**We promise to**:
- Honor Mark's vision and lived experience
- Ensure no one else has to self-diagnose
- Transform his patent innovations into patient impact
- Protect his children's generation through early detection
- Build a lasting institution worthy of his name
- Never lose sight of why this foundation exists

---

## üìå How We Make Decisions

**Our Decision-Making Framework** (in order):

1. **Does it help patients?** (Patient First)
2. **Is it evidence-based?** (Science-driven)
3. **Can we do it urgently?** (Speed matters)
4. **Do we have the right partners?** (Collaboration)
5. **Is it innovative or incremental?** (Prefer innovation)
6. **Can we measure impact?** (Data-driven)
7. **Are we being transparent?** (Openness)
8. **Does it inspire hope?** (Optimism)

If the answer to #1 is "no" or unclear, we don't do it‚Äîregardless of other factors.

---

## üå± Living Document

This Mission, Vision & Values statement is **not static**. We commit to:
- **Annual review** by the Board of Directors
- **Updates** based on evolving science and patient needs
- **Input** from patients, donors, and partners
- **Transparency** when we evolve or pivot

**Next Review**: November 2026

---

## üìû Contact

**Mark Egly Foundation**  
Website: https://markeglyfoundation.com (new design coming soon)  
Patient Community: https://alpha1life.com (launching 2026)  
Email: info@markeglyfoundation.com  
Phone: [To be determined]

**For Media Inquiries**: media@markeglyfoundation.com  
**For Partnership Inquiries**: partnerships@markeglyfoundation.com  
**For Patient Support**: support@markeglyfoundation.com

---

**Approved by**: Mark Egly Foundation Board of Directors  
**Effective Date**: November 7, 2025  
**Version**: 1.0  
**Next Review**: November 2026

---

*"No one should have to self-diagnose a genetic condition. Together, we end diagnostic delays for AATD."*

**‚Äî Mark Egly, Founder**
